aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
November 09, 2022 08:00 ET
|
aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...
TILLY’S LIFE CENTER WELCOMES NEW CEO, COLLEEN VERSTEEG
November 03, 2022 17:02 ET
|
tilly's life center
Orange County, California, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Tilly’s Life Center (TLC), a non-profit organization dedicated to supporting teen mental health, recently announced the addition of...
aTyr Pharma to Present at the Jefferies London Healthcare Conference
October 25, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
TILLY’S LIFE CENTER RAISES NEARLY $600,000 AT ITS “I AM GIVING” GALA
October 19, 2022 14:10 ET
|
tilly's life center
Orange County, CA, Oct. 19, 2022 (GLOBE NEWSWIRE) -- On the evening of October 8, 2022, Tilly’s Life Center (TLC) raised nearly $600,000 at its 8th Annual “I Am Giving” Gala. This year’s event was...
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
October 11, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...
aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
October 04, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
September 29, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
September 27, 2022 08:00 ET
|
aTyr Pharma, Inc.
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. ...
Experience a Pirate’s Life in Multiplayer Arcade Brawler Plunder Panic, Out Now With Crossplay Between All Major Consoles and Windows PC/Mac
September 16, 2022 10:00 ET
|
Will Winn Games
EAST LANSING, Mich., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ahoy, Me Hearties! Hoist the Jolly Roger and sharpen those cutlasses, as Will Winn Games’ pirate-themed online multiplayer brawler Plunder...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
September 13, 2022 08:00 ET
|
aTyr Pharma, Inc.
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE)...